Vascular inflammation sits at the root of atherosclerosis, acute lung injury, and a constellation of cardiovascular disorders that collectively represent the leading cause of preventable death globally. Understanding what flips endothelial cells — the thin lining of blood vessels — from a quiescent state into a pro-inflammatory one could open entirely new therapeutic avenues beyond the lipid-lowering and anti-platelet strategies that dominate current care.
Published in PNAS, this study identifies Polycomb Repressive Complex 2 (PRC2) as a master epigenetic switch governing how endothelial cells respond to disturbed blood flow — the kind of turbulent, low-shear hemodynamic environment found at arterial bends and bifurcations where plaques preferentially form. PRC2 is a chromatin-modifying complex best known for silencing gene expression via trimethylation of histone H3 at lysine 27 (H3K27me3). The research demonstrates that flow conditions modulate PRC2 activity to drive endothelial cells toward inflammatory transcriptional programs, implicating epigenetic remodeling — not just acute signaling cascades — as a durable mechanism sustaining vascular disease states.
This finding is significant for several reasons. Epigenetic regulators like PRC2 have gained enormous traction in oncology, where PRC2 inhibitors (EZH2 inhibitors such as tazemetostat) are already FDA-approved. The cardiovascular field has been slower to embrace epigenetic therapeutics, but this work suggests a mechanistic rationale for doing so. From a broader research landscape perspective, the discovery aligns with an emerging body of work showing that atherosclerosis is not merely a lipid storage disease but a chronic inflammatory condition with epigenetic memory — meaning vessel walls can be "trained" into pathological states that persist even after risk factors are controlled. Key limitations include the need for human in vivo validation, as mechanistic vascular biology frequently involves model systems that do not fully recapitulate human hemodynamics. Overall, this is an incrementally paradigm-shifting contribution that reframes vascular inflammation as an epigenetically encoded phenomenon with targetable upstream regulators.